Immune responses against drugs and vectors limit the efficacy and reach of biotherapeutics. Ablevia’s injectable pre-treatment clears harmful antibodies, unlocking the full potential of advanced therapies and targeted drug delivery.
Removing harmful anti-drug and anti-vector antibodies
By clearing antibodies against biotherapeutics and delivery systems, we aim to restore drug function, enable repeat dosing, and open lifechanging treatments to patients who are currently excluded due to preexisting anti-drug immunity.
When Antibodies Limit Treatment
A common immunogenicity issue for modern and emerging biotherapeutics across oncology, rare and metabolic diseases, as well as gene and RNA therapies.
Pre-existing and treatment-emergent anti-drug and anti–delivery platform antibodies (including anti-PEG) limit patient eligibility, reduce exposure and pharmacodynamic response, and preclude redosing due to accelerated clearance and neutralization.
Selective Antibody Depletion Approach
Ablevia’s injectable Selective Antibody Depletion Compounds (SADCs) act as molecular decoys that remove circulating anti-drug antibodies, before treatment.
Selective antibody removal that unlocks the full value of advanced therapies
Ablevia’s rapid, immune-sparing pre-treatment removes anti-drug and anti-vector antibodies, restoring drug pharmacokinetics and delivery so therapies can work as intended. This expands patient eligibility and enables safer repeat dosing with more durable treatment value.
Enabling therapies through selective antibody removal
Ablevia provides a selective antibody removal pre-treatment platform, built on our Selective Antibody Depletion Compounds (SADCs), for partners developing advanced biologics and delivery systems.
Our lead SADC program rapidly removes anti-PEG antibodies before dosing, restoring the performance of PEGylated drugs and enabling RNA and DNA delivery via PEGylated LNPs. Building on this, we are advancing nextgeneration SADCs that target protein-targeted anti-drug and anti-vector antibodies, guided by deep profiling of ADA epitopes to systematically expand eligible patient populations.
Our team brings experience in antibody engineering, viral vectors, and biologics development. We combine scientific expertise with translational and partnering experience.
Founder
Scientist and biotech innovator leading the development of first-in-class antibody-targeting therapeutics. With a background in vaccine and antibody development, and experience across leading academic and biotech environments, he has driven novel approaches from early discovery to translational development.
Co-Founder
Entrepreneur bridging science and strategy, focused on advancing novel biologic technologies into high-impact partnerships. With experience across venture, biotech, and strategic development, he translates innovation into scalable growth and industry collaborations
Ablevia is backed by experienced industry leaders and strategic investors with deep expertise in biologics and gene therapy. The board includes Dr. Friedrich Scheiflinger, former Head of R&D at Takeda, executive at Evotec Gene Therapy, and founder, who brings decades of experience in rare diseases and advanced therapeutics. This is complemented by advisory expertise in strategy, valuation, and regulatory development across biologics, vaccines, oncology, and rare diseases, further strengthened by gene therapy–focused investors and global networks.